Literature DB >> 29380275

In Schizophrenia, Depression, Anxiety, and Physiosomatic Symptoms Are Strongly Related to Psychotic Symptoms and Excitation, Impairments in Episodic Memory, and Increased Production of Neurotoxic Tryptophan Catabolites: a Multivariate and Machine Learning Study.

Buranee Kanchanatawan1, Supaksorn Thika1, Sunee Sirivichayakul2, André F Carvalho3,4, Michel Geffard5,6, Michael Maes7,8,9.   

Abstract

The depression, anxiety and physiosomatic symptoms (DAPS) of schizophrenia are associated with negative symptoms and changes in tryptophan catabolite (TRYCAT) patterning. The aim of this study is to delineate the associations between DAPS and psychosis, hostility, excitation, and mannerism (PHEM) symptoms, cognitive tests as measured using the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) and IgA/IgM responses to TRYCATs. We included 40 healthy controls and 80 participants with schizophrenia. Depression and anxiety symptoms were measured with The Hamilton Depression (HAM-D) and Anxiety (HAM-A) Rating Scales, respectively. Physiosomatic symptoms were assessed with the Fibromyalgia and Chronic Fatigue Syndrome Rating Scale (FF). Negative symptoms as well as CERAD tests, including Verbal Fluency Test (VFT), Mini-Mental State Examination (MMSE), Word List Memory (WLM), and WL Delayed Recall were measured, while ratios of IgA responses to noxious/protective TRYCATs (IgA NOX_PRO) were computed. Schizophrenia symptoms consisted of two dimensions, a first comprising PHEM and negative symptoms, and a second DAPS symptoms. A large part of the variance in DAPS was explained by psychotic symptoms and WLM. Of the variance in HAM-D, 58.9% was explained by the regression on excitement, IgA NOX_PRO ratio, WLM, and VFT; 29.9% of the variance in HAM-A by psychotic symptoms and IgA NOX/PRO; and 45.5% of the variance in FF score by psychotic symptoms, IgA NOX/PRO, and WLM. Neural network modeling shows that PHEM, IgA NOX_PRO, WLM, and MMSE are the dominant variables predicting DAPS. DAPS appear to be driven by PHEM and negative symptoms coupled with impairments in episodic memory, especially false memory creation, while all symptom dimension and cognitive impairments may be driven by an increased production of noxious TRYCATs, including picolinic, quinolinic, and xanthurenic acid.

Entities:  

Keywords:  Anxiety; Depression; Immune; Inflammation; Schizophrenia; Tryptophan catabolites

Mesh:

Substances:

Year:  2018        PMID: 29380275     DOI: 10.1007/s12640-018-9868-4

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  42 in total

1.  Depressive, anxiety and hypomanic symptoms in schizophrenia may be driven by tryptophan catabolite (TRYCAT) patterning of IgA and IgM responses directed to TRYCATs.

Authors:  Buranee Kanchanatawan; Sunee Sirivichayakul; André F Carvalho; George Anderson; Piotr Galecki; Michael Maes
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2017-07-08       Impact factor: 5.067

2.  Depressive and anxiety symptoms in patients with schizophrenia and schizophreniform disorder.

Authors:  R A Emsley; P P Oosthuizen; A F Joubert; M C Roberts; D J Stein
Journal:  J Clin Psychiatry       Date:  1999-11       Impact factor: 4.384

3.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery.

Authors:  K A Welsh; N Butters; R C Mohs; D Beekly; S Edland; G Fillenbaum; A Heyman
Journal:  Neurology       Date:  1994-04       Impact factor: 9.910

4.  IgM-mediated autoimmune responses directed against anchorage epitopes are greater in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) than in major depression.

Authors:  Michael Maes; Ivana Mihaylova; Marta Kubera; Jean-Claude Leunis; Frank N M Twisk; Michel Geffard
Journal:  Metab Brain Dis       Date:  2012-05-22       Impact factor: 3.584

5.  Attention and memory deficits in schizophrenia: the role of symptoms of depression.

Authors:  Christine Möser; Jürgen C Krieg; Josef Zihl; Stefan Lautenbacher
Journal:  Cogn Behav Neurol       Date:  2006-09       Impact factor: 1.600

6.  Age, gender, and education norms on the CERAD neuropsychological battery in the oldest old.

Authors:  M S Beeri; J Schmeidler; M Sano; J Wang; R Lally; H Grossman; J M Silverman
Journal:  Neurology       Date:  2006-09-26       Impact factor: 9.910

7.  The two-syndrome concept: origins and current status.

Authors:  T J Crow
Journal:  Schizophr Bull       Date:  1985       Impact factor: 9.306

Review 8.  The role of negative symptoms and cognitive dysfunction in schizophrenia outcome.

Authors:  C A Tamminga; R W Buchanan; J M Gold
Journal:  Int Clin Psychopharmacol       Date:  1998-03       Impact factor: 1.659

9.  Inflammatory and cell-mediated immune biomarkers in myalgic encephalomyelitis/chronic fatigue syndrome and depression: inflammatory markers are higher in myalgic encephalomyelitis/chronic fatigue syndrome than in depression.

Authors:  Michael Maes; Frank N M Twisk; Karl Ringel
Journal:  Psychother Psychosom       Date:  2012-07-20       Impact factor: 17.659

Review 10.  A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis.

Authors:  Justin Davis; Harris Eyre; Felice N Jacka; Seetal Dodd; Olivia Dean; Sarah McEwen; Monojit Debnath; John McGrath; Michael Maes; Paul Amminger; Patrick D McGorry; Christos Pantelis; Michael Berk
Journal:  Neurosci Biobehav Rev       Date:  2016-04-09       Impact factor: 8.989

View more
  8 in total

1.  The Neuroimmune and Neurotoxic Fingerprint of Major Neurocognitive Psychosis or Deficit Schizophrenia: a Supervised Machine Learning Study.

Authors:  Hussein Kadhem Al-Hakeim; Abbas F Almulla; Michael Maes
Journal:  Neurotox Res       Date:  2020-01-08       Impact factor: 3.911

2.  Breakdown of the Paracellular Tight and Adherens Junctions in the Gut and Blood Brain Barrier and Damage to the Vascular Barrier in Patients with Deficit Schizophrenia.

Authors:  Michael Maes; Sunee Sirivichayakul; Buranee Kanchanatawan; Aristo Vodjani
Journal:  Neurotox Res       Date:  2019-05-10       Impact factor: 3.911

Review 3.  False dogmas in mood disorders research: Towards a nomothetic network approach.

Authors:  Michael Hj Maes; Drozdstoy Stoyanov
Journal:  World J Psychiatry       Date:  2022-05-19

4.  In Schizophrenia, Deficits in Natural IgM Isotype Antibodies Including those Directed to Malondialdehyde and Azelaic Acid Strongly Predict Negative Symptoms, Neurocognitive Impairments, and the Deficit Syndrome.

Authors:  Michael Maes; Buranee Kanchanatawan; Sunee Sirivichayakul; André F Carvalho
Journal:  Mol Neurobiol       Date:  2018-11-27       Impact factor: 5.590

5.  Chronic fatigue syndrome and fibromyalgia-like symptoms are an integral component of the phenome of schizophrenia: neuro-immune and opioid system correlates.

Authors:  Rana Fadhil Mousa; Hussein Kadhem Al-Hakeim; Amer Alhaideri; Michael Maes
Journal:  Metab Brain Dis       Date:  2020-09-23       Impact factor: 3.584

6.  Immune System Abnormalities in Schizophrenia: An Integrative View and Translational Perspectives.

Authors:  Evgeny A Ermakov; Mark M Melamud; Valentina N Buneva; Svetlana A Ivanova
Journal:  Front Psychiatry       Date:  2022-04-25       Impact factor: 5.435

7.  Cinnamaldehyde Improves Lifespan and Healthspan in Drosophila melanogaster Models for Alzheimer's Disease.

Authors:  Hanh M Pham; Anna Xu; Samuel E Schriner; Evgueni A Sevrioukov; Mahtab Jafari
Journal:  Biomed Res Int       Date:  2018-08-29       Impact factor: 3.411

8.  Using machine learning-based analysis for behavioral differentiation between anxiety and depression.

Authors:  Thalia Richter; Barak Fishbain; Andrey Markus; Gal Richter-Levin; Hadas Okon-Singer
Journal:  Sci Rep       Date:  2020-10-02       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.